Dare Bioscience Inc. announced the commercial rollout of DARE to PLAY™ Sildenafil Cream, the first evidence-backed topical arousal cream developed specifically for women. Supported by multiple clinical trials, including a randomized placebo-controlled study with 200 women and peer-reviewed research published in leading medical journals, the cream has been shown to increase genital blood flow within 10-15 minutes and improve arousal sensations. While the company continues to pursue FDA approval, DARE to PLAY™ is now available by prescription in select states as a Section 503B compounded product. The research supporting the product has already been published in journals such as The Green Journal and the Journal of Sexual Medicine.